Compare DLHC & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLHC | RFL |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Business Services | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.4M | 92.6M |
| IPO Year | 2012 | 2017 |
| Metric | DLHC | RFL |
|---|---|---|
| Price | $5.09 | $2.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.6K | ★ 245.4K |
| Earning Date | 05-06-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,923,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.57 | ★ 43.96 |
| 52 Week Low | $5.03 | $1.12 |
| 52 Week High | $8.09 | $3.96 |
| Indicator | DLHC | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 43.37 |
| Support Level | $5.08 | $1.21 |
| Resistance Level | $5.66 | $3.96 |
| Average True Range (ATR) | 0.17 | 0.26 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 11.29 | 16.00 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.